Halda Therapeutics is advancing a proprietary RIPTAC™ modality, a heterobifunctional "hold and kill" approach that brings together a cancer-specific protein and an essential protein to selectively kill cancer cells. The company’s lead candidate, HLD-0915, is expected to enter a Phase 1 clinical trial in the first half of 2025 for metastatic, castration-resistant prostate cancer (mCRPC). Halda is also advancing a second RIPTAC program toward clinical development in metastatic breast cancer. Proceeds from the recent financing will support these IND-enabling and early clinical activities, help build the team, and fund additional RIPTAC programs for other indications. The company was founded by Professor Craig Crews of Yale and is located in New Haven, CT. Including the new financing, Halda has raised $202 million to date.

Total raised

$126M

Funding rounds

1

Latest round

Series B

Latest activity

Aug 2024